Answers are grounded in this paper and cite their sources.
Our results confirm the potency of INSTI on HIV-2 clinical isolates with wild-type integrase. In addition, we identified a new resistance pathway, 231INS, selected in antiretroviral-experienced patients with multiresistant HIV-2 viruses. This highlights the need of close follow-up of those patients initiating an INSTI-based regimen.
No takes yet. Share an insight, caveat, or question.
Hingrat et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: